SG11201504164VA - 6-((S)-1-{1-[5-(2-HYDROXY-ETHOXY)-PYRIDIN-2-YL]-1<i>H</i>-PYRAZOL-3-YL}-ETHYL)-3<i>H</i>-1,3-BENZOTHIAZOL-2-ONE AS A TARP-GAMMA 8 DEPENDENT AMPA RECEPTOR ANTAGONIST - Google Patents

6-((S)-1-{1-[5-(2-HYDROXY-ETHOXY)-PYRIDIN-2-YL]-1<i>H</i>-PYRAZOL-3-YL}-ETHYL)-3<i>H</i>-1,3-BENZOTHIAZOL-2-ONE AS A TARP-GAMMA 8 DEPENDENT AMPA RECEPTOR ANTAGONIST

Info

Publication number
SG11201504164VA
SG11201504164VA SG11201504164VA SG11201504164VA SG11201504164VA SG 11201504164V A SG11201504164V A SG 11201504164VA SG 11201504164V A SG11201504164V A SG 11201504164VA SG 11201504164V A SG11201504164V A SG 11201504164VA SG 11201504164V A SG11201504164V A SG 11201504164VA
Authority
SG
Singapore
Prior art keywords
tarp
benzothiazol
pyrazol
pyridin
ethoxy
Prior art date
Application number
SG11201504164VA
Other languages
English (en)
Inventor
Jon Kevin Reel
Warren Jaye Porter
Jeffrey Michael Witkin
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of SG11201504164VA publication Critical patent/SG11201504164VA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201504164VA 2012-11-27 2013-11-20 6-((S)-1-{1-[5-(2-HYDROXY-ETHOXY)-PYRIDIN-2-YL]-1<i>H</i>-PYRAZOL-3-YL}-ETHYL)-3<i>H</i>-1,3-BENZOTHIAZOL-2-ONE AS A TARP-GAMMA 8 DEPENDENT AMPA RECEPTOR ANTAGONIST SG11201504164VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261730273P 2012-11-27 2012-11-27
PCT/US2013/070885 WO2014085153A1 (en) 2012-11-27 2013-11-20 6-((s)-1-{1-[5-(2-hydroxy-ethoxy)-pyridin-2-yl]-1h-pyrazol-3-yl}- ethyl)-3h-1,3-benzothiazol-2-one as a tarp-gamma 8 dependent ampa receptor antagonist

Publications (1)

Publication Number Publication Date
SG11201504164VA true SG11201504164VA (en) 2015-07-30

Family

ID=49753484

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201504164VA SG11201504164VA (en) 2012-11-27 2013-11-20 6-((S)-1-{1-[5-(2-HYDROXY-ETHOXY)-PYRIDIN-2-YL]-1<i>H</i>-PYRAZOL-3-YL}-ETHYL)-3<i>H</i>-1,3-BENZOTHIAZOL-2-ONE AS A TARP-GAMMA 8 DEPENDENT AMPA RECEPTOR ANTAGONIST

Country Status (35)

Country Link
US (1) US8765960B2 (https=)
EP (1) EP2925754B1 (https=)
JP (1) JP6246227B2 (https=)
KR (1) KR101693133B1 (https=)
CN (1) CN104797578B (https=)
AP (1) AP2015008489A0 (https=)
AR (1) AR093527A1 (https=)
AU (1) AU2013352594B2 (https=)
BR (1) BR112015011200A2 (https=)
CA (1) CA2889243C (https=)
CL (1) CL2015001419A1 (https=)
CR (1) CR20150267A (https=)
CY (1) CY1118657T1 (https=)
DK (1) DK2925754T3 (https=)
DO (1) DOP2015000113A (https=)
EA (1) EA026686B1 (https=)
ES (1) ES2618260T3 (https=)
HR (1) HRP20170274T1 (https=)
HU (1) HUE033447T2 (https=)
IL (1) IL238831B (https=)
JO (1) JO3225B1 (https=)
MA (1) MA38126B1 (https=)
MX (1) MX356478B (https=)
MY (1) MY177721A (https=)
PE (1) PE20151728A1 (https=)
PH (1) PH12015501154B1 (https=)
PL (1) PL2925754T3 (https=)
PT (1) PT2925754T (https=)
SG (1) SG11201504164VA (https=)
SI (1) SI2925754T1 (https=)
TN (1) TN2015000200A1 (https=)
TW (2) TW201825484A (https=)
UA (1) UA114345C2 (https=)
WO (1) WO2014085153A1 (https=)
ZA (1) ZA201503733B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201609719A (zh) 2014-05-28 2016-03-16 美國禮來大藥廠 作為TARP-γ8依賴性AMPA受體拮抗劑之6-經取代-3H-1,3-苯并噻唑-2-酮化合物
US10604484B2 (en) 2015-04-29 2020-03-31 Janssen Pharmaceutica Nv Indolone compounds and their use as AMPA receptor modulators
RS61688B1 (sr) 2015-04-29 2021-05-31 Janssen Pharmaceutica Nv Azabenzimidazoli i njihiova upotreba kao modulatori ampa receptora
WO2016176457A1 (en) 2015-04-29 2016-11-03 Janssen Pharmaceutica Nv Imidazopyrazines and pyrazolopyrimidines and their use as ampa receptor modulators
AU2016255424B2 (en) * 2015-04-29 2020-10-08 Janssen Pharmaceutica Nv Benzimidazolone and benzothiazolone compounds and their use as AMPA receptor modulators
EP3532477B1 (en) * 2016-10-26 2020-08-26 Janssen Pharmaceutica NV Fused bicylic pyridine compounds and their use as ampa receptor modulators
RU2650523C1 (ru) * 2017-07-24 2018-04-16 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Производное пиридоксина для лечения эпилепсии
RU2703286C1 (ru) * 2019-06-18 2019-10-16 федеральное государственное автономное образовательное учреждение высшего образования "Казанский (Приволжский) федеральный университет" (ФГАОУ ВО КФУ) Соли (5-гидрокси-3,4-бис(гидроксиметил)-6-метилпиридин-2-ил)метансульфокислоты и способ их получения

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY132385A (en) * 1995-08-31 2007-10-31 Novartis Ag 2,3-dioxo-1,2,3,4-tetrahydro-quinoxalinyl derivatives
JP2000281676A (ja) * 1999-01-25 2000-10-10 Yamanouchi Pharmaceut Co Ltd Ampa拮抗化合物の新規製造法
IL152848A0 (en) * 2000-06-12 2003-06-24 Eisai Co Ltd 1,2-dihydropyridine derivatives, pharmaceutical compositions containing the same and methods for the production thereof
US8995993B2 (en) * 2000-10-11 2015-03-31 Gogo Llc System for managing mobile internet protocol addresses in an airborne wireless cellular network
MX2007007226A (es) * 2004-12-17 2007-08-21 Lilly Co Eli Antagonistas receptores novedosos de hormona concentradora de melanina (mch).
WO2007076161A2 (en) 2005-12-27 2007-07-05 Myriad Genetics, Inc Compounds with therapeutic activity
TW200817385A (en) * 2006-07-04 2008-04-16 Organon Nv Heterocyclic derivatives
CA2739559A1 (en) * 2008-10-08 2010-04-15 Pfizer Inc. Tetrahydrofuranyl sulfonamides and pharmaceutical compositions thereof
HUE025013T2 (hu) * 2009-01-12 2016-04-28 Pfizer Ltd Szulfonamid-származékok
CN102985420B (zh) * 2010-06-01 2017-07-04 安吉翁生物医药有限公司 细胞色素p450抑制剂及其用途
EP2694472B1 (en) * 2011-04-05 2020-03-11 Takeda Pharmaceutical Company Limited Sulfonamide derivative and use thereof
TW201609719A (zh) 2014-05-28 2016-03-16 美國禮來大藥廠 作為TARP-γ8依賴性AMPA受體拮抗劑之6-經取代-3H-1,3-苯并噻唑-2-酮化合物

Also Published As

Publication number Publication date
AU2013352594A1 (en) 2015-06-04
CA2889243C (en) 2017-06-13
JP6246227B2 (ja) 2017-12-13
EP2925754B1 (en) 2016-12-28
CL2015001419A1 (es) 2015-10-02
EA026686B1 (ru) 2017-05-31
HK1209116A1 (en) 2016-03-24
SI2925754T1 (sl) 2017-02-28
KR20150070401A (ko) 2015-06-24
CY1118657T1 (el) 2017-07-12
HRP20170274T1 (hr) 2017-04-07
CN104797578B (zh) 2016-11-23
AP2015008489A0 (en) 2015-05-31
MY177721A (en) 2020-09-23
WO2014085153A1 (en) 2014-06-05
AR093527A1 (es) 2015-06-10
MA38126A1 (fr) 2017-03-31
PH12015501154A1 (en) 2015-08-10
MX2015006697A (es) 2015-08-05
AU2013352594B2 (en) 2016-02-18
HUE033447T2 (en) 2017-11-28
DOP2015000113A (es) 2015-06-15
TW201434834A (zh) 2014-09-16
CR20150267A (es) 2015-09-16
TWI618705B (zh) 2018-03-21
US20140148441A1 (en) 2014-05-29
CA2889243A1 (en) 2014-06-05
PT2925754T (pt) 2017-02-27
DK2925754T3 (en) 2017-02-20
MA38126B1 (fr) 2017-11-30
EA201590823A1 (ru) 2015-08-31
MX356478B (es) 2018-05-30
WO2014085153A8 (en) 2014-07-31
IL238831A0 (en) 2015-06-30
PE20151728A1 (es) 2015-12-02
JP2016501219A (ja) 2016-01-18
BR112015011200A2 (pt) 2017-07-11
ZA201503733B (en) 2017-09-27
JO3225B1 (ar) 2018-03-08
TN2015000200A1 (en) 2016-10-03
UA114345C2 (uk) 2017-05-25
ES2618260T3 (es) 2017-06-21
PL2925754T3 (pl) 2017-07-31
US8765960B2 (en) 2014-07-01
TW201825484A (zh) 2018-07-16
EP2925754A1 (en) 2015-10-07
KR101693133B1 (ko) 2017-01-04
CN104797578A (zh) 2015-07-22
PH12015501154B1 (en) 2018-05-30
IL238831B (en) 2018-08-30

Similar Documents

Publication Publication Date Title
SG11201504164VA (en) 6-((S)-1-{1-[5-(2-HYDROXY-ETHOXY)-PYRIDIN-2-YL]-1&lt;i&gt;H&lt;/i&gt;-PYRAZOL-3-YL}-ETHYL)-3&lt;i&gt;H&lt;/i&gt;-1,3-BENZOTHIAZOL-2-ONE AS A TARP-GAMMA 8 DEPENDENT AMPA RECEPTOR ANTAGONIST
ME03556B (me) 3-[4-(7h-pirolo[2,3-d]pirimidin-4-il)-1 h-pirazol-1-il]oktan- ili нертan - niтril kао јак inhibiтori
IL208355A0 (en) Heterocyclic copmpounds as adenosine receptor antagonist
ZA201106117B (en) Graphical user interface for search request management
IL212436A0 (en) Isonicotinamide orexin receptor antagonists
AP2011005817A0 (en) Substituted piperidines as CCR3 antagonists.
ZA201207292B (en) Cgrp receptor antagonist
LT2862860T (lt) 1,3-oksazolidino arba 1,3-oksazinano junginiai kaip oreksino receptoriaus antagonistai
PT3077390T (pt) Forma de sal cristalino de (s)-(2-(6-cloro-7-metil-1hbenzo[d]imidazol-2-il)-2-metilpirrolidin-1-il)(5-metoxi-2-(2h-1,2,3-triazol-2-il)fenil)metanona como antagonista do recetor de orexina
PL2817312T3 (pl) Nowe związki będące antagonistami receptora neurokininy 1
IL213982A0 (en) Piperidine derivatives as nk3 receptor antagonists
EP2370425A4 (en) IMIDAZOLE DERIVATIVES CONDENSED AS TRPV3 ANTAGONISTS
PT2257534E (pt) Antagonistas 3-aminoalquil-1,4-diazepan-2-ona do recetor 5 da melanocortina
ZA201301143B (en) Heterocyclyl compounds as histamine h3 receptor ligands
IL210927A0 (en) 6-substituted benzoxazines as 5-ht-5a receptor antagonists
IL223060A (en) Non-competitive antagonists for the nicotinic receptor
ZA201202150B (en) [1,4]-benzodiazepines as vasopressin v2 receptor antagonists
IL213769A0 (en) Piperidine derivatives as nk3 receptor antagonists
IL207438A0 (en) 2-aminoquinolines as 5-ht5a receptor antagonists
GB201013708D0 (en) [1,4]-Benzodiazepines as vasopressin v2 receptor antagonists
GB0916792D0 (en) (1,4)-Benzodiazepines as vasopressin V2 receptor antagonists